Dopamine News and Research

Latest Dopamine News and Research

Stem cell study may help to unravel how genetic mutation leads to Parkinson's symptoms

By reprogramming skin cells from Parkinson's disease patients with a known genetic mutation, researchers at the Salk Institute for Biological Studies have identified damage to neural stem cells as a powerful player in the disease.

20 Oct 2012

Nonmotor symptoms common in early-stage PD

Nonmotor symptoms occur in nearly all individuals with Parkinson’s disease, Italian study results suggest.

17 Oct 2012

Hereditary genes responsible for pain severity after motor vehicle collisions

Two studies presented at the ANESTHESIOLOGY 2012 annual meeting found that hereditary genes were responsible for the amount and type of pain experienced after a motor vehicle collision (MVC).

17 Oct 2012

Mephedrone and memory loss: an interview with Craig Motbey

Mephedrone is a fairly new designer drug which has been around for a few years. It exploded in popularity in Europe (and particularly in the UK) before it started to spread in a major way elsewhere.

16 Oct 2012

Animal research shows promise in treating AD, brain damage and heart problems resulting from SCIs

New animal studies provide additional support for investigating stem cell treatments for Parkinson's disease, head trauma, and dangerous heart problems that accompany spinal cord injury, according to research findings released today.

16 Oct 2012

Mother rats respond much differently to cocaine than non-mothers

Mother rats respond much differently to cocaine than female rats that have never given birth, according to new University of Michigan research that looks at both behavior and brain chemistry.

16 Oct 2012

Rapamycin may delay onset of Parkinson's or AD

Rapamycin, a drug used to prevent rejection in transplants, could delay the onset of neurodegenerative diseases such as Alzheimer's and Parkinson's.

16 Oct 2012

GE Healthcare launches new online patient and caregiver resource for Parkinson's disease

As part of GE Healthcare's ongoing commitment to provide resources for those living with movement disorders, the company announced today a new online patient and caregiver resource - www.Move2Answers.com.

15 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

New insights into how brain responds to extreme stress

Researchers report new insights into how the brain responds to extreme stress, whether from combat, natural disasters, or repeated violent competition. The insights offer hope for detecting and treating several widespread and debilitating neuropsychiatric disorders, and were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

Investigators provide overview of role of dopamine in modulating the immune system

Dopamine is a neurotransmitter that is associated with emotions, movement, and the brain's pleasure and reward system. In the current issue of Advances in Neuroimmune Biology, investigators provide a broad overview of the direct and indirect role of dopamine in modulating the immune system and discuss how recent research has opened up new possibilities for treating diseases such as Parkinson's and Alzheimer's disease, schizophrenia, multiple sclerosis or even the autoimmune disorders.

11 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

Kynurenic acid levels increased in bipolar patients with psychotic features

Bipolar disorder patients with a history of psychotic features have higher cerebrospinal fluid concentrations of kynurenic acid (KYNA) than those without such features, research shows.

9 Oct 2012

Translational Genomics Research Institute creates new center for rare childhood disorders

The Translational Genomics Research Institute (TGen) today announced the creation of a new center that could have life changing effects on the lives of potentially thousands of children and their families.

6 Oct 2012

Kisspeptin reverses hyperprolactinemia-induced ovarian acyclicity

Kisspeptin neurons appear to play a role in hypogonadotropic anovulation caused by excessive levels of prolactin, research shows.

1 Oct 2012

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012

Teva concludes Asset Transfer Agreement with NeuroSearch

Teva Pharmaceutical Industries Ltd announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark to purchase all rights, assets and obligations relating to Huntexil (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD).

28 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012